Since the expansion of WAT mass seen in obesity involves hyperplasia, hypertrophy, inflammation, and glucose turnover in adipocytes, the beneficial effects of GDF11 therapy in obesity are likely to occur at multiple levels. Here, GDF11 is linked to obesity due to melanocortin 4 receptor deficiency.